Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Meiji Holdings
Tokyo, Japan
- Ownership
- Public · 2269
- Development stage
- Other
01
Overview
Meiji Holdings operates commercially with multiple approved products including KOSTAIVE (world's first approved self-amplifying mRNA COVID-19 vaccine, approved November 2023, updated for JN.1 variant in September 2024). The company has ongoing Phase III clinical trials for KD-414 (inactivated COVID-19 vaccine) in both adults and children, updated to target JN.1 strain as of April 2025. Global Phase III trials for OP0595 (nacubactam), a novel β-lactamase inhibitor for antimicrobial-resistant bacteria, commenced in April 2023 across 17 countries and received orphan drug designation in November 2024.
- Therapeutic areas
- ImmunologyNeurologyInfectious DiseasesHematologyPsychiatryOncology
- Modalities
- VaccineSmall moleculeAntibacterial drugImmunoglobulinmRNA-based drugsBlood plasma productsRecombinant protein
- Industry
- Biotech
02
Partnerships
ARCALIS (COVID-19 vaccine manufacturing)Kitasato Institute (ivermectin derivatives R&D)National research institutes (vaccine development)Medreich (generic pharmaceuticals)
Beyond the preview
Go deeper on Meiji Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meiji Holdings.